Replies to post #198102 on Biotech Values

[DewDiligence]

CHRS -14% on required re-do of Neulasta-FoB bioequivalence study (#msg-119019743).

In contrast to CHRS’ +10% move on Oct 2—which showed profound misunderstanding by investors of the 351(k) regulatory pathway (#msg-117437374)—today’s 14% drop seems about right.

CHRS’ management lost a lot of credibility with the heavy BS in yesterday's PR and the way they handled this incident in general.

[DewDiligence]

CHRS +8% on redone PK study for Neulasta FoB:

http://finance.yahoo.com/news/coherus-announces-positive-topline-results-123000984.html

The PR says a “BLA” submission is expected during the current quarter; they presumably mean a 351(k) submission.